ArticleClinical research in cardiology : official journal of the German Cardiac Society2021
Pacemaker lead-associated tricuspid regurgitation in patients with or without pre-existing right ventricular dilatation.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Evolution and prognosis of tricuspid and mitral regurgitation following cardiac implantable electronic devices: a systematic review and meta-analysis.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024Pooled it
- Impact of stylet-driven lead for left bundle branch area pacing on tricuspid valve function: A comparative analysis with conventional CRT.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026Article
- Left and Right Heart Remodelling at 1 Year After Transcatheter Versus Surgical Aortic Valve Replacement: A Speckle-Tracking Echocardiography Study.Interdisciplinary cardiovascular and thoracic surgery · 2026Article
- Transvenous Lead Extraction for Tricuspid Regurgitation and Right Atrial Enlargement Induced by an Atrial Lead.JACC. Case reports · 2026Article
- [Research of tricuspid regurgitation associated with cardiac implantable electronic devices].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025Review
- AI and Smart Devices in Cardio-Oncology: Advancements in Cardiotoxicity Prediction and Cardiovascular Monitoring.Diagnostics (Basel, Switzerland) · 2025Review
- Comparing the effects of left bundle branch pacing and leadless right ventricular pacing on intraventricular and interventricular dyssynchrony usingFrontiers in physiology · 2025Article
- Tricuspid Regurgitation in the Setting of Cardiac Implantable Electronic Devices.Structural heart : the journal of the Heart Team · 2025Review
- Tricuspid valve complication following leadless pacemaker implantation requiring device extraction.HeartRhythm case reports · 2024Article
- Sex-Specific Insights into Etiology, Diagnosis, Treatment, and Prognosis in Significant Tricuspid Regurgitation: A Narrative Review.Biomedicines · 2024Review
- Tricuspid Regurgitation Associated with Implantable Cardiac Devices: A Double-Edged Sword.Journal of clinical medicine · 2024Review
- New Therapeutic Advances in the Management of Tricuspid Valve Regurgitation.Journal of clinical medicine · 2024Review
- Change in Tricuspid Valve Function after Transvenous Lead Extraction, Predisposing Factors and Prognostic Roles.Reviews in cardiovascular medicine · 2024Article
- Tricuspid valve disease and cardiac implantable electronic devices.European heart journal · 2024Review
- Tricuspid Regurgitation (TR) after Implantation of a Cardiac Implantable Electronic Device (CIED)-One-Year Observation of Patients with or without Left Ventricular Dysfunction.Journal of cardiovascular development and disease · 2023Article
- Identification of Pacemaker Lead Position Using Fluoroscopy to Avoid Significant Tricuspid Regurgitation.Journal of clinical medicine · 2023Article
- Update on Percutaneous Treatment for HFrEF: A Great Armamentarium for a Poor Ventricular Function.Reviews in cardiovascular medicine · 2023Review
- Valvular Heart Disease Epidemiology.Medical sciences (Basel, Switzerland) · 2022Review
- Multi-Modality Imaging of the Tricuspid Valve: From Tricuspid Valve Disease to Catheter-Based Interventions.Reviews in cardiovascular medicine · 2022Review
- Atrial Mitral and Tricuspid Regurgitation: Sex Matters. A Call for Action to Unravel the Differences Between Women and Men.Frontiers in cardiovascular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
Abstract
backgroundTranscatheter tricuspid valve intervention became an option for pacemaker lead-associated tricuspid regurgitation. This study investigated the progression of tricuspid regurgitation (TR) in patients with or without pre-existing right ventricular dilatation (RVD) undergoing pacemaker implantation.
methodsPatients were included if they had implantation of transtricuspid pacemaker lead and completed echocardiography before and after implantation. The cohort was divided in patients with and without RVD (cut-off basal RV diameter ≥ 42 mm). TR was graded in none/mild, moderate, and severe. Worsening of one grade was defined as progression. Survival analyses were plotted for 10 years.
resultsIn total, 990 patients were analyzed (24.5% with RVD). Progression of TR occurred in 46.1% of patients with RVD and in 25.6% of patients without RVD (P < 0.001). Predictors for TR progression were RV dilatation (OR 2.04; 95% CI 1.27-3.29; P = 0.003), pre-existing TR (OR 4.30; 95% CI 2.51-7.38; P < 0.001), female sex (OR 1.68; 95% CI 1.16-2.43; P = 0.006), single RV lead (OR 1.67; 95% CI 1.09-2.56; P = 0.018), mitral regurgitation (OR 2.08; 95% CI 1.42-3.05; P < 0.001), and enlarged left atrium (OR 1.98; 95% CI 1.07-3.67; P = 0.03). Survival-predictors were pacemaker lead-associated TR (HR 1.38; 95% CI 1.04-1.84; P = 0.028), mitral regurgitation (HR 1.34; 95% CI 1.02-1.77; P = 0.034), heart failure (HR 1.75; 95% CI 1.31-2.33; P < 0.001), kidney disease (HR 1.62; 95% CI 1.25-2.11; P < 0.001), and age ≥ 80 years (HR 2.84; 95% CI 2.17-3.71; P < 0.001).
conclusionsPatients with RVD receiving pacemaker suffered from increased TR progression, leading to decreased survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.